Cytokinetics Rises After Promising Late-Stage Trial of Heart Drug

Dow Jones

05/05

By Rob Curran

Shares of Cytokinetics rallied after one of the biopharmaceutical company's product candidates showed promise in a late-stage trial for patients with a heart condition.

The South San Francisco, Calif., company's aficamten met primary end-points in a Phase 3 trial for patients with non-obstructive hypertrophic cardiomyopathy. Patients taking the treatment showed statistically significant improvements in exercise capacity and symptom burden, the company said.

No new safety concerns arose during the trial. Left ventricular ejection fraction below 50% occurred in 27 patients taking aficamten, and two patients suffered a serious adverse event of heart failure.

Shares of Cytokinetics rose 21% to $80.08 premarket.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

May 05, 2026 08:56 ET (12:56 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2633943114"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2633943114\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2633943114?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-05 20:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633943114","market":"us","top_or_hot":-1,"title":"Cytokinetics Rises After Promising Late-Stage Trial of Heart Drug","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Rob Curran \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/CYTK\">Cytokinetics</a> rallied after one of the biopharmaceutical company's product candidates showed promise in a late-stage trial for patients with a heart condition. \n</p>\n<p>\n  The South San Francisco, Calif., company's aficamten met primary end-points in a Phase 3 trial for patients with non-obstructive hypertrophic cardiomyopathy. Patients taking the treatment showed statistically significant improvements in exercise capacity and symptom burden, the company said. \n</p>\n<p>\n  No new safety concerns arose during the trial. Left ventricular ejection fraction below 50% occurred in 27 patients taking aficamten, and two patients suffered a serious adverse event of heart failure. \n</p>\n<p>\n  Shares of Cytokinetics rose 21% to $80.08 premarket. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 05, 2026 08:56 ET (12:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cytokinetics Rises After Promising Late-Stage Trial of Heart Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCytokinetics Rises After Promising Late-Stage Trial of Heart Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-05 20:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Rob Curran \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/CYTK\">Cytokinetics</a> rallied after one of the biopharmaceutical company's product candidates showed promise in a late-stage trial for patients with a heart condition. \n</p>\n<p>\n  The South San Francisco, Calif., company's aficamten met primary end-points in a Phase 3 trial for patients with non-obstructive hypertrophic cardiomyopathy. Patients taking the treatment showed statistically significant improvements in exercise capacity and symptom burden, the company said. \n</p>\n<p>\n  No new safety concerns arose during the trial. Left ventricular ejection fraction below 50% occurred in 27 patients taking aficamten, and two patients suffered a serious adverse event of heart failure. \n</p>\n<p>\n  Shares of Cytokinetics rose 21% to $80.08 premarket. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 05, 2026 08:56 ET (12:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2633943114","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2633943114","pubTimestamp":1777985760,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Cytokinetics rallied after one of the biopharmaceutical company's product candidates showed promise in a late-stage trial for patients with a heart condition.The South San Francisco, Calif., company's aficamten met primary end-points in a Phase 3 trial for patients with non-obstructive hypertrophic cardiomyopathy. Patients taking the treatment showed statistically significant improvements in exercise capacity and symptom burden, the company said.No new safety concerns arose during the trial. Left ventricular ejection fraction below 50% occurred in 27 patients taking aficamten, and two patients suffered a serious adverse event of heart failure.Shares of Cytokinetics rose 21% to $80.08 premarket.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4139":"生物科技","CYTK":"Cytokinetics","BK4588":"碎股"},"translate_title":"心脏药物后期试验后细胞动力学上升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYTK":1.5,"SSI":1.5},"content_text":"By Rob Curran \n\n\n \n\n\n  Shares of Cytokinetics rallied after one of the biopharmaceutical company's product candidates showed promise in a late-stage trial for patients with a heart condition. \n\n\n  The South San Francisco, Calif., company's aficamten met primary end-points in a Phase 3 trial for patients with non-obstructive hypertrophic cardiomyopathy. Patients taking the treatment showed statistically significant improvements in exercise capacity and symptom burden, the company said. \n\n\n  No new safety concerns arose during the trial. Left ventricular ejection fraction below 50% occurred in 27 patients taking aficamten, and two patients suffered a serious adverse event of heart failure. \n\n\n  Shares of Cytokinetics rose 21% to $80.08 premarket. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@dowjones.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 05, 2026 08:56 ET (12:56 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}